NTLA Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -687.61% compared to Intellia Therapeutics's net margin of --. Intellia Therapeutics's return on equity of -56.9% beat Perspective Therapeutics's return on equity of --.

Intellia Therapeutics has a consensus price target of $37.30, signalling upside risk potential of 350.44%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.2692 which suggests that it could grow by 341.77%. Given that Intellia Therapeutics has higher upside potential than Perspective Therapeutics, analysts believe Intellia Therapeutics is more attractive than Perspective Therapeutics.

Intellia Therapeutics has a beta of 2.141, which suggesting that the stock is 114.144% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.093, suggesting its more volatile than the S&P 500 by 9.29%.

Intellia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intellia Therapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Intellia Therapeutics quarterly revenues are $16.6M, which are larger than Perspective Therapeutics quarterly revenues of --. Intellia Therapeutics's net income of -$114.3M is lower than Perspective Therapeutics's net income of -$18.2M. Notably, Intellia Therapeutics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intellia Therapeutics is 18.32x versus 22.77x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -687.61% compared to Intellia Therapeutics's net margin of 12.06%. Intellia Therapeutics's return on equity of -56.9% beat Electromed's return on equity of 16.57%.

Intellia Therapeutics has a consensus price target of $37.30, signalling upside risk potential of 350.44%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 86.68%. Given that Intellia Therapeutics has higher upside potential than Electromed, analysts believe Intellia Therapeutics is more attractive than Electromed.

Intellia Therapeutics has a beta of 2.141, which suggesting that the stock is 114.144% more volatile than S&P 500. In comparison Electromed has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.159%.

Intellia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intellia Therapeutics pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Intellia Therapeutics quarterly revenues are $16.6M, which are larger than Electromed quarterly revenues of $15.7M. Intellia Therapeutics's net income of -$114.3M is lower than Electromed's net income of $1.9M. Notably, Intellia Therapeutics's price-to-earnings ratio is -- while Electromed's PE ratio is 25.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intellia Therapeutics is 18.32x versus 2.89x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

TransMedics Group has a net margin of -687.61% compared to Intellia Therapeutics's net margin of 17.89%. Intellia Therapeutics's return on equity of -56.9% beat TransMedics Group's return on equity of 23.22%.

Intellia Therapeutics has a consensus price target of $37.30, signalling upside risk potential of 350.44%. On the other hand TransMedics Group has an analysts' consensus of $129.57 which suggests that it could fall by -7.05%. Given that Intellia Therapeutics has higher upside potential than TransMedics Group, analysts believe Intellia Therapeutics is more attractive than TransMedics Group.

Intellia Therapeutics has a beta of 2.141, which suggesting that the stock is 114.144% more volatile than S&P 500. In comparison TransMedics Group has a beta of 2.097, suggesting its more volatile than the S&P 500 by 109.735%.

Intellia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TransMedics Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intellia Therapeutics pays -- of its earnings as a dividend. TransMedics Group pays out -- of its earnings as a dividend.

Intellia Therapeutics quarterly revenues are $16.6M, which are smaller than TransMedics Group quarterly revenues of $143.5M. Intellia Therapeutics's net income of -$114.3M is lower than TransMedics Group's net income of $25.7M. Notably, Intellia Therapeutics's price-to-earnings ratio is -- while TransMedics Group's PE ratio is 102.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intellia Therapeutics is 18.32x versus 10.43x for TransMedics Group. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -687.61% compared to Intellia Therapeutics's net margin of 0.18%. Intellia Therapeutics's return on equity of -56.9% beat Xtant Medical Holdings's return on equity of -26.62%.

Intellia Therapeutics has a consensus price target of $37.30, signalling upside risk potential of 350.44%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 161.19%. Given that Intellia Therapeutics has higher upside potential than Xtant Medical Holdings, analysts believe Intellia Therapeutics is more attractive than Xtant Medical Holdings.

Intellia Therapeutics has a beta of 2.141, which suggesting that the stock is 114.144% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.181, suggesting its less volatile than the S&P 500 by 118.091%.

Intellia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intellia Therapeutics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Intellia Therapeutics quarterly revenues are $16.6M, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. Intellia Therapeutics's net income of -$114.3M is lower than Xtant Medical Holdings's net income of $58K. Notably, Intellia Therapeutics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intellia Therapeutics is 18.32x versus 0.75x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.